Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedJul 07, 2026
DataAggregated Company Financials
Companies20
  • 7D2.5%
  • 3M28.7%
  • 1Y-22.5%
  • YTD-4.7%

The Healthcare industry is up 2.5% in the last week, with Novo Nordisk up 2.0%. However, the industry is down 23% over the past year. Earnings are forecast to grow by 1.7% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 07 Jul 2026DKK 1.9tDKK 469.1bDKK 147.1b20.7x12.6x4x
Thu, 04 Jun 2026DKK 1.6tDKK 468.7bDKK 147.0b19.3x11x3.4x
Sat, 02 May 2026DKK 1.6tDKK 447.4bDKK 129.9b18.6x12.4x3.6x
Mon, 30 Mar 2026DKK 1.4tDKK 447.8bDKK 130.1b16.6x10.9x3.2x
Wed, 25 Feb 2026DKK 1.5tDKK 447.7bDKK 131.0b18.7x11.6x3.4x
Fri, 23 Jan 2026DKK 2.3tDKK 453.8bDKK 136.9b18.7x16.5x5x
Sun, 21 Dec 2025DKK 1.9tDKK 453.8bDKK 136.9b16.9x13.7x4.1x
Tue, 18 Nov 2025DKK 1.9tDKK 454.1bDKK 137.0b17.1x13.8x4.2x
Thu, 16 Oct 2025DKK 2.1tDKK 447.6bDKK 141.7b18.3x15x4.7x
Sat, 13 Sep 2025DKK 2.0tDKK 447.3bDKK 141.7b19.9x14.4x4.6x
Mon, 11 Aug 2025DKK 1.9tDKK 434.8bDKK 132.5b28.7x14.2x4.3x
Wed, 09 Jul 2025DKK 2.5tDKK 423.0bDKK 124.5b30.7x19.7x5.8x
Fri, 06 Jun 2025DKK 2.6tDKK 423.7bDKK 124.6b30.8x20.7x6.1x
Sun, 04 May 2025DKK 2.5tDKK 409.3bDKK 121.3b23x20.6x6.1x
Tue, 01 Apr 2025DKK 2.6tDKK 409.5bDKK 121.3b23.1x21.1x6.2x
Thu, 27 Feb 2025DKK 3.4tDKK 410.0bDKK 121.4b28.8x28x8.3x
Sat, 25 Jan 2025DKK 3.3tDKK 387.4bDKK 111.3b29.4x29.8x8.6x
Mon, 23 Dec 2024DKK 3.1tDKK 387.4bDKK 111.3b28.7x28.2x8.1x
Wed, 20 Nov 2024DKK 3.8tDKK 387.3bDKK 111.3b32.1x33.8x9.7x
Fri, 18 Oct 2024DKK 4.2tDKK 372.1bDKK 107.2b37.3x39.2x11.3x
Sun, 15 Sep 2024DKK 4.7tDKK 372.0bDKK 107.1b36x43.8x12.6x
Tue, 13 Aug 2024DKK 4.6tDKK 370.3bDKK 107.0b36.1x42.6x12.3x
Thu, 11 Jul 2024DKK 4.9tDKK 355.3bDKK 106.2b35.6x46.3x13.9x
Sat, 08 Jun 2024DKK 4.9tDKK 355.3bDKK 106.2b36.2x46.5x13.9x
Mon, 06 May 2024DKK 4.3tDKK 354.8bDKK 106.4b33.9x40.9x12.3x
Wed, 03 Apr 2024DKK 4.5tDKK 341.2bDKK 99.6b38.4x44.7x13.1x
Fri, 01 Mar 2024DKK 4.2tDKK 340.1bDKK 98.9b38.2x42.9x12.5x
Sun, 28 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b34.7x42x11.8x
Tue, 26 Dec 2023DKK 3.6tDKK 320.4bDKK 90.0b32.8x40.2x11.3x
Thu, 23 Nov 2023DKK 3.6tDKK 320.5bDKK 90.0b32.7x40.4x11.4x
Sat, 21 Oct 2023DKK 3.5tDKK 305.5bDKK 82.2b27.8x42.6x11.5x
Mon, 18 Sep 2023DKK 3.5tDKK 305.5bDKK 82.2b36.6x42.9x11.5x
Wed, 16 Aug 2023DKK 3.3tDKK 301.3bDKK 81.0b40x40.9x11x
Fri, 14 Jul 2023DKK 2.9tDKK 286.9bDKK 75.4b38.3x38x10x
Price to Earnings Ratio

38x


Total Market Cap: DKK 2.9tTotal Earnings: DKK 75.4bTotal Revenue: DKK 286.9bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 29.1x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 12.6x which is lower than its 3-year average PE of 29.1x.
  • The 3-year average PS ratio of 8.4x is higher than the industry's current PS ratio of 4.0x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 25% per year over the last three years.
  • Revenues for these companies have grown 18% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market3.38%
Healthcare2.49%
Biotech6.33%
Life Sciences6.16%
Medical Equipment5.67%
Pharma1.75%
Healthcare Services0.97%
Healthtech-0.62%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry, which is trading close to its 3-year average PE ratio of 32.9x.
    • Analysts are expecting annual earnings growth of 19.6%, which is higher than its past year's earnings growth of 0.3% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 113% over the next 5 years.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 7.7% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVO B Novo NordiskDKK 321.102.0%
+DKK 27.4b		-27.2%PE11.7x
GMAB GenmabDKK 1.83k6.3%
+DKK 6.7b		39.7%PE20.9x
COLO B ColoplastDKK 397.605.3%
+DKK 4.5b		-33.2%PE42.5x
DEMANT DemantDKK 281.206.3%
+DKK 3.5b		6.4%PE25x
AMBU B AmbuDKK 66.758.7%
+DKK 1.4b		-31.7%PE36.9x

Latest News

GMAB
DKK 1,827.50
Genmab
7D
6.3%
1Y
39.7%
CHEMM
DKK 409.60
ChemoMetec
7D
12.2%
1Y
-25.6%
NOVO B
DKK 321.10
Novo Nordisk
7D
2.0%
1Y
-27.2%
AMBU B
DKK 66.75
Ambu
7D
8.7%
1Y
-31.7%
Narrative Update • Jul 01

AMBU B: Rising Competition Will Weigh On Future Share Performance

The analyst price target for Ambu has been reduced from DKK 78 to DKK 58, with analysts citing a more cautious near term outlook and rising competition as key reasons for the change. Analyst Commentary Recent commentary on Ambu reflects a more cautious tone, with bearish analysts flagging concerns around the company’s ability to deliver against expectations as competition increases.
COLO B
DKK 397.60
Coloplast
7D
5.3%
1Y
-33.2%
Narrative Update • Jun 30

COLO B: Reset Expectations And New Products Will Shape Future Sentiment

The analyst price target for Coloplast has been revised from DKK 535 to DKK 345. This reflects a reset in valuation assumptions as analysts weigh recent target cuts against differing views on how the recent share selloff relates to company fundamentals and future P/E expectations.
BAVA
DKK 190.20
Bavarian Nordic
7D
5.7%
1Y
12.1%
ALK B
DKK 241.60
ALK-Abelló
7D
-3.6%
1Y
28.5%
Narrative Update • Jun 26

ALK B: Paediatric Allergy Approvals Will Drive Future Immunotherapy Leadership

Analysts have raised their price target on ALK-Abelló from DKK 243 to DKK 305, citing the company's position as a global leader in allergy immunotherapy as a key factor in their updated view. What’s in the News for ALK-Abelló UK regulator MHRA granted marketing authorisation for EURneffy 1 mg, the first needle free adrenaline treatment for anaphylaxis in children aged 4 and older weighing 15 to less than 30 kg, expanding ALK-Abelló’s emergency allergy treatment options in the UK.
ZEAL
DKK 300.70
Zealand Pharma
7D
6.9%
1Y
-17.1%
Narrative Update • Jun 25

ZEAL: Obesity Pipeline Progress And Buybacks Will Support Future Re Rating

Zealand Pharma's analyst price target has moved from about DKK 825 to roughly DKK 300, as analysts point to a longer timeline to unlock upside, lower peak sales expectations for key pipeline drugs, and revised assumptions that include a higher future P/E multiple and softer projected growth and margins. Analyst Commentary Recent Street research on Zealand Pharma highlights a mix of caution and optimism, with several analysts revisiting their assumptions on valuation, execution timelines, and the growth potential of key pipeline assets such as petrelintide and survodutide.
GUBRA
DKK 320.60
Gubra
7D
-1.0%
1Y
-25.5%
Narrative Update • Jun 24

GUBRA: Upcoming Phase 2 Obesity Milestone Will Support Long Term Upside

Analysts have kept their DKK 451.50 price target for Gubra unchanged, citing only minor tweaks to the discount rate and future P/E assumptions, without a shift in their overall valuation view. What's in the News for Gubra Gubra highlighted that partner Boehringer Ingelheim plans to start Phase 2 clinical development in mid 2026 for BI 3034701, a potential first in class triple GLP-1, GIP and NPY2 receptor agonist peptide for obesity and related metabolic diseases, based on Gubra discovered technology.
DEMANT
DKK 281.20
Demant
7D
6.3%
1Y
6.4%
Narrative Update • Jun 23

DEMANT: Fair Value View Balances Growth Inflection Hopes With Execution Risks

Analysts have lifted their price expectations for Demant, with the consensus fair value estimate moving from DKK 240.32 to DKK 251.11. Recent research points to a higher price target range supported by updated views on growth, profitability and future P/E multiples.
NNIT
DKK 37.90
NNIT
7D
-2.1%
1Y
-45.4%
VIRO
DKK 10.20
ViroGates
7D
-6.4%
1Y
18.6%
PEG
DKK 0.082
Pharma Equity Group
7D
-5.1%
1Y
-34.2%
STRAP
DKK 530.00
Strategic Partners
7D
-3.6%
1Y
-47.3%